VICP · Vicapsys Life Sciences, Inc. · Debt
$0.50
At close · Nov 4
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jan 10, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern and to operate in the normal course of business within one year after the date that the financial statements are issued.”View the 10-Q filed Jan 10, 2025
Market Cap
$16.19M
Shares
32.37M
Volume · Nov 4
1400
Avg daily vol (23 sessions)
3964
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of convertible notes payable | 2024-09-30 | USD 511,403 | 10-Q filed 2025-01-10 |
| Short-term bank loans and notes payable | 2024-09-30 | USD 12,546 | 10-Q filed 2025-01-10 |
| Short-term non-bank loans and notes payable | 2024-09-30 | USD 55,000 | 10-Q filed 2025-01-10 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.